<DOC>
	<DOC>NCT01034657</DOC>
	<brief_summary>This study assessed the efficacy and safety of LBH589 as single agent and in combination with ESA in red blood cell transfusion-dependent Low and Int-1 MDS patients being either refractory to ESA or with a low probability of response. The study had a non-randomized core phase followed by a randomized phase.</brief_summary>
	<brief_title>LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS)</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Key Patients with a lower risk MDS (LOW or INT1 according to IPSS) Red blood cell transfusion dependency of at least 4 Units/8 weeks. Not responding to Erythropoietin stimulating agents (ESA) or having a low chance to do so Ageadjusted normal cardiac, kidney, liver function Key Concomitant use of ESA Concomitant use of any other investigational drug Other malignancy that is not in remission for at least 1 year Platelet Count &lt; 75 x 109/L Impaired cardiac function or clinically significant cardiac diseases</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>MDS</keyword>
	<keyword>bone marrow</keyword>
	<keyword>anemia</keyword>
	<keyword>cytopenia</keyword>
	<keyword>transfusion dependance</keyword>
	<keyword>EPO</keyword>
	<keyword>ESA</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>LBH589</keyword>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>hematopoietic improvement</keyword>
	<keyword>IPSS Low</keyword>
	<keyword>IPSS Int-1</keyword>
	<keyword>HI-E</keyword>
	<keyword>HDAC Inhibitor</keyword>
	<keyword>HDAC-I</keyword>
	<keyword>DAC-I</keyword>
	<keyword>Deacetylase-Inhibitor</keyword>
	<keyword>Histone Deacetylase-Inhibitor</keyword>
	<keyword>red blood cell transfusions</keyword>
</DOC>